Yuhan, Luoxin deal

Luoxin said it was unable to complete a deal with Yuhan that would have granted Luoxin rights to YH25448, which is in preclinical testing for non-small cell lung cancer (NSCLC). Last July, the companies entered a term sheet to negotiate for the rights to the third-generation tyrosine kinase inhibitor (TKI), which targets both the initial EGFR-activating mutation and the T790M EGFR-resistance mutation. ...